GET THE APP

July 31, 2021    Brussels, Belgium

2nd Webinar on

Hematology and Genetic Blood Disorders

slider
July 31, 2021   08:30 AM GMT  
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
  

2nd Webinar on

Hematology and Genetic Blood Disorders

Briefly Know About This Event

2nd Webinar on Hematology and Genetic Blood Disorders will be hosted on June 30th 2021 as per UK Time Zone (GMT+1). Panel of speakers will be delivering their presentations on their recent research related to Hematology and Genetic Blood Disorders. The current state of knowledge, its impact on the future will be discussed in detailed. Longdom Conferences invites all experts to be part of this webinar series and make it a perfect platform for knowledge sharing and networking.

Main theme of the webinar is Forefront fundamental research and innovation in Hematology

                                                                                                                                            

Sessions

A blood cell disorder is a condition in which there is a problem with our red blood cells, white blood cells, or the smaller circulating cells called platelets, which are critical for clot formation. All cell types form in the bone marrow, which is the soft tissue inside our bones. Red blood cells carry oxygen to our body’s organs and tissues. White blood cells help our body fight infections. Platelets help our blood to clot. Blood cell disorders damage the formation and function of one or more of these types of blood cells. Some symtoms include:

  • Fatigue,
  • Shortness of breath,
  • Difficulty in concentration from lack of oxygenated blood in the,
  • Brain,
  • Muscle weakness,
  • Fast heartbeat,
  • Chronic infections rapid weight loss,
  • General feeling of being unwell,
  • Sores that don’t heal or are slow to heal,
  • Blood that doesn’t clot after cut or an injury,
  • Skin that bruises easily,
  • Unexplained nosebleeds and bleeding from the gums.

Hemostasis is the cessation of bleeding from a cut or severed vessel, whereas thrombosis occurs when the endothelium lining blood vessels is damaged or removed. These processes involve blood vessels, Plasma protein, and platelet aggregation that cause formation or dissolution of platelet aggregates and fibrin.

In hemostasis, there is initial vasoconstriction of the injured vessel, resulting in diminished blood flow distal to the injury. Then, hemostasis and thrombosis share following phases:

  • Formation of a temporary and loose platelet aggregate at the site of injury. Platelets bind to collagen at the site of vessel wall injury, form thromboxane A2,  release ADP, which activate other platelets flowing by the vicinity of the injury.
  • Formation of a fibrin mesh that binds to the platelet aggregate, forming a more stable hemostatic plug/thrombus.
  • Partial or complete dissolution of the hemostatic plug/thrombus by plasmin.

A blood transfusion is a way of adding blood to our body after an illness or injury. If our body is missing one or more of the components that make up healthy blood, a transfusion can help supply what our body is missing. Depending on how much blood we need, a transfusion can take between 1 and 4 hours.

Our blood is made up of several different parts including red and white cells, plasma, and platelets. “Whole blood” refers to blood that has all of them. In some cases, we may need to have a transfusion that uses whole blood, but it’s more likely that we will need a specific component.

There are many reasons we might need to receive a blood transfusion. These are just a few of them:

  • We have had major surgery or a serious injury and we need to replace lost blood
  • We have experienced bleeding in our digestive tract from an ulcer or other condition
  • We have received cancer treatments like radiation or chemotherapy
  • We have a blood disorder or severe liver problems

Cardiovascular problems through blood and therefore the system that gives laboratory values regarding blood, the circulatory system and secures  cardiovascular diseases from the Chinese medicine and western medicine perspectives.

Cardio-Oncology is to seek out a balance between oncologic efficacy and reducing antagonistic cardiovascular results over timely publication and broadcasting of research. Cardiac imaging and transthoracic echocardiography play an important role within the baseline assessment and serial follow-up of cardio-oncology patients. Scientific indication in the administration of cardiovascular jerks of onco-hematological patients is unusual, as these patients have been systematically omitted from clinical trials and up-to-date approvals are based on expert consent. Cardio-hematology which permit its claim in regular clinical preparation so to market the expansion of local multidisciplinary crews, to rally the cardiovascular health of patients with cancer.

The crossing point between hematology and neurology is broad, and neurological complications within the course of hematologic ailment are recurrent and diverse. Polycythaemia, in which there are increased numbers of red blood cells with iron deficient. Polycythaemia and therefore the comparative Sideropenia cause amplified blood viscosity with connected neurological symptoms and signs. Haematological conditions that lead into neurological manifestations are Thrombophilia, antiphospholipid antibody syndrome, thrombotic thrombocytopenic purpura, sickle cell, myeloma, leukemias, lymphomas and clonal disorders. These are considered into amiable and malignant situations.

Immunohematology is the study of reactions that take place between antigens present on blood cells and antibodies present in plasma. Patients undergoing transfusion therapy are tested for their ABO and RhD blood groups and the presence of any antibodies that may create a reaction between their plasma and donor red cells. A range of tests are available to use to detect and identify antibodies in the patient's plasma from simple tube and gel tests to more complex absorption and elution techniques as well as advanced molecular techniques. These same tests will also identify if the antigen is present on the patient's red cells. For patients with hematological conditions such as auto immune hemolytic anemia, a wide range of immune-hematological techniques are used to identify and resolve the diagnostic problems in these patients. Molecular techniques are increasingly used in immunohematology to determine the antigen profile of patients, resolve complex problems and large scale red cell typing.

The IACH  (International Academy for Clinical Hematology) is founded by an international group of physicians whose focus is to stimulate good clinical practice in the field of clinical hematology. There is a rapid grow in global demand for academic continuing education of hematologists comprising clinical skills for patient management, standardization of real-life treatment procedures, as well in the performance of routine and comprehensive care in different fields of hematology. Actually, hematology is likely the most dynamic medical specialty with respect to new pathophysiology findings and their implementation in new therapies. The development of new drugs (targeted therapies, immunotherapy, etc.) is accompanied by a growing demand for sharing experiences in order to improve the quality of patient treatment and care via the development of professional competencies and excellence. In order to attain these objectives, cooperation is needed amongst the health professionals worldwide under a common umbrella to promote health care capacities by sharing scientific and clinical knowledge, methods and skills.

The worldwide market of the hematological medications is in top point because it is usually anticipated to be enhanced over the few decades. As per the worldwide market expert the hematology medicate and expressive market is relied upon to develop at the rate of 7.5% from 2015-2021. Some of the highest pharmaceutical industries producing Biological Drugs and Generic Drugs incorporate. Bristol-Mayers Squibb, Boehringer Ingelheim, Roche, Novartis, Celgene, Johnson and Johnson, Lilly, Takeda, AstraZeneca, Merck and Co., Amgen, Janssen biotech, Pfizer, Astellas, Bayer, Otsuka, Sanofi, Eisai, AbbVie, Merck KGaA, Pharmacyclics and Incyte.

  • Biological drugs
  • Generic drugs
  • Increased investments
  • Healthcare expenditures

Blood hematologic cancers generally begin in the bone marrow where blood is produced. Stem cells in the bone marrow grow into white blood cells, red blood cells, or platelets. Blood cancers occur when uncontrolled growth of abnormal blood cells overtakes the development of normal blood cells and interferes with the regular functions of these cells. Blood cancers are of three categories: leukemia, lymphoma, and myeloma.

Myeloma is a type of cancer that occurs in plasma cells. Normal plasma cells develop antibodies that fight disease and infection. Though, when abnormal myeloma cells develop, they interfere with the antibody production and lead to lessened immunity. 

If our child or teen has a blood disease or cancer, a pediatric haematologist  has the experience and qualifications to evaluate and treat our child or teen. The uncommon nature of care of children or teens with blood diseases and cancer is learned from advanced training and experience in practice. Pediatric hematologists  treat children and youth from birth through young adulthood.

Pediatric hematologists/oncologists diagnose and treat children and teens with the following:

  • Cancers including leukemias, lymphomas, brain tumors, solid  tumors, and bone tumors
  • Diseases of blood cells including disorders of white cells, red cells, and platelets
  • Bleeding disorders

Our Brilliant Speakers

LONGDOM conferences speaker bureau map future challenges through ideation sessions by designing and validating new ideas with end users by placing right speakers in front of right audience at the right time.

What Client's Say

We let our ground-breaking work and our amazing clients speak for us…… LONGDOM conferences

  [email protected]
  [email protected]
  [email protected]
Speakers Interview